1
|
Filippi F, Baraldi C, Zinzani P, Casadei B, Pileri A. A case of pityriasis lichenoides et varioliformis acuta developed after first dose of Oxford-AstraZeneca COVID-19 vaccine. J Eur Acad Dermatol Venereol 2022; 36:e747-e749. [PMID: 35617206 PMCID: PMC9348115 DOI: 10.1111/jdv.18269] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2022] [Accepted: 05/18/2022] [Indexed: 01/19/2023]
Affiliation(s)
- F. Filippi
- Department of Experimental, Diagnostic and Specialty MedicineAlma Mater Studiorum University of BolognaBolognaItaly,Dermatology UnitIRCCS Azienda Ospedaliero‐Universitaria di BolognaBolognaItaly
| | - C. Baraldi
- Department of Experimental, Diagnostic and Specialty MedicineAlma Mater Studiorum University of BolognaBolognaItaly,Dermatology UnitIRCCS Azienda Ospedaliero‐Universitaria di BolognaBolognaItaly
| | - P.L. Zinzani
- IRCCS Azienda Ospedaliero, Istituto di Ematologia ‘Seràgnoli’Università di BolognaBolognaItaly
| | - B. Casadei
- IRCCS Azienda Ospedaliero, Istituto di Ematologia ‘Seràgnoli’Università di BolognaBolognaItaly
| | - A. Pileri
- Department of Experimental, Diagnostic and Specialty MedicineAlma Mater Studiorum University of BolognaBolognaItaly,Dermatology UnitIRCCS Azienda Ospedaliero‐Universitaria di BolognaBolognaItaly
| |
Collapse
|
2
|
Chiappella A, Guidetti A, Dodero A, Bramanti S, Zinzani P, Santoro A, Casadei B, Di Rocco A, Carrabba M, Chiusolo P, Martino M, Barbui AM, Tisi MC, Miceli R, Carniti C, Corradini P. FIRST REPORT OF THE REAL‐LIFE PROSPECTIVE OBSERVATIONAL STUDY “CAR‐T CELL IN DIFFUSE LARGE B‐CELL AND PRIMARY MEDIASTINAL LYMPHOMAS” OF THE ITALIAN SOCIETY OF HEMATOLOGY. Hematol Oncol 2021. [DOI: 10.1002/hon.187_2880] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- A. Chiappella
- Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Hematology and Stem Cell Transplantation Milano Italy
| | - A. Guidetti
- Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Hematology and Stem Cell Transplantation Milano Italy
| | - A. Dodero
- Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Hematology and Stem Cell Transplantation Milano Italy
| | - S. Bramanti
- Humanitas Clinical and Research Center IRCCS Hematology Rozzano Italy
| | - P. Zinzani
- University of Bologna Institute of Hematology "Seràgnoli" Bologna Italy
| | - A. Santoro
- Humanitas Clinical and Research Center IRCCS Hematology Rozzano Italy
| | - B. Casadei
- University of Bologna Institute of Hematology "Seràgnoli" Bologna Italy
| | - A. Di Rocco
- 'Sapienza' University of Rome Department of Translational and Precision Medicine Roma Italy
| | - M. Carrabba
- San Raffaele Hospital IRCCS Hematology and Bone Marrow Transplantation Unit Milano Italy
| | - P. Chiusolo
- Fondazione Policlinico Universitario A. Gemelli IRCCS Università Cattolica del Sacro Cuore Department of Diagnostica per Immagini Radioterapia Oncologica ed Ematologia Hematology Section Department of Scienze Radiologiche ed Ematologiche Roma Italy
| | - M. Martino
- Grande Ospedale Metropolitano “Bianchi‐Melacrino‐Morelli” Stem Cell Transplant and Cellular Therapies Unit Reggio Calabria Italy
| | - A. M. Barbui
- Azienda Socio Sanitaria Territoriale (ASST), Ospedale Papa Giovanni XXIII Hematology Unit Bergamo Italy
| | - M. C. Tisi
- San Bortolo Hospital Cell Therapy and Hematology Vicenza Italy
| | - R. Miceli
- Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Unit of Clinical Epidemiology and Trial Organization Department of Applied Research and Technological Development Milano Italy
| | - C. Carniti
- Fondazione IRCCS Istituto Nazionale dei Tumori Milano, Italy Laboratory of Hematology Division of Hematology and Stem Cell Transplantation Milano Italy
| | - P. Corradini
- Chair of Hematology University of Milano Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Division of Hematology and Stem Cell Transplantation Milano Italy
| |
Collapse
|
3
|
Scarisbrick JJ, Quaglino P, Prince HM, Papadavid E, Hodak E, Bagot M, Servitje O, Berti E, Ortiz-Romero P, Stadler R, Patsatsi A, Knobler R, Guenova E, Child F, Whittaker S, Nikolaou V, Tomasini C, Amitay I, Prag Naveh H, Ram-Wolff C, Battistella M, Alberti-Violetti S, Stranzenbach R, Gargallo V, Muniesa C, Koletsa T, Jonak C, Porkert S, Mitteldorf C, Estrach T, Combalia A, Marschalko M, Csomor J, Szepesi A, Cozzio A, Dummer R, Pimpinelli N, Grandi V, Beylot-Barry M, Pham-Ledard A, Wobser M, Geissinger E, Wehkamp U, Weichenthal M, Cowan R, Parry E, Harris J, Wachsmuth R, Turner D, Bates A, Healy E, Trautinger F, Latzka J, Yoo J, Vydianath B, Amel-Kashipaz R, Marinos L, Oikonomidi A, Stratigos A, Vignon-Pennamen MD, Battistella M, Climent F, Gonzalez-Barca E, Georgiou E, Senetta R, Zinzani P, Vakeva L, Ranki A, Busschots AM, Hauben E, Bervoets A, Woei-A-Jin FJSH, Matin R, Collins G, Weatherhead S, Frew J, Bayne M, Dunnill G, McKay P, Arumainathan A, Azurdia R, Benstead K, Twigger R, Rieger K, Brown R, Sanches JA, Miyashiro D, Akilov O, McCann S, Sahi H, Damasco FM, Querfeld C, Folkes A, Bur C, Klemke CD, Enz P, Pujol R, Quint K, Geskin L, Hong E, Evison F, Vermeer M, Cerroni L, Kempf W, Kim Y, Willemze R. The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients. Br J Dermatol 2019; 181:350-357. [PMID: 30267549 DOI: 10.1111/bjd.17258] [Citation(s) in RCA: 112] [Impact Index Per Article: 22.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/25/2018] [Indexed: 12/16/2022]
Abstract
BACKGROUND Survival in mycosis fungoides (MF) is varied and may be poor. The PROCLIPI (PROspective Cutaneous Lymphoma International Prognostic Index) study is a web-based data collection system for early-stage MF with legal data-sharing agreements permitting international collaboration in a rare cancer with complex pathology. Clinicopathological data must be 100% complete and in-built intelligence in the database system ensures accurate staging. OBJECTIVES To develop a prognostic index for MF. METHODS Predefined datasets for clinical, haematological, radiological, immunohistochemical, genotypic, treatment and quality of life are collected at first diagnosis of MF and annually to test against survival. Biobanked tissue samples are recorded within a Federated Biobank for translational studies. RESULTS In total, 430 patients were enrolled from 29 centres in 15 countries spanning five continents. Altogether, 348 were confirmed as having early-stage MF at central review. The majority had classical MF (81·6%) with a CD4 phenotype (88·2%). Folliculotropic MF was diagnosed in 17·8%. Most presented with stage I (IA: 49·4%; IB: 42·8%), but 7·8% presented with enlarged lymph nodes (stage IIA). A diagnostic delay between first symptom development and initial diagnosis was frequent [85·6%; median delay 36 months (interquartile range 12-90)]. This highlights the difficulties in accurate diagnosis, which includes lack of a singular diagnostic test for MF. CONCLUSIONS This confirmed early-stage MF cohort is being followed-up to identify prognostic factors, which may allow better management and improve survival by identifying patients at risk of disease progression. This study design is a useful model for collaboration in other rare diseases, especially where pathological diagnosis can be complex.
Collapse
Affiliation(s)
- J J Scarisbrick
- European Co-ordinating PROCLIPI Centre for PROCLIPI, University Hospitals Birmingham, Birmingham, U.K
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
- Member of the UK Cutaneous Lymphoma Group
| | - P Quaglino
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - H M Prince
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - E Papadavid
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - E Hodak
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - M Bagot
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - O Servitje
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - E Berti
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - P Ortiz-Romero
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - R Stadler
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - A Patsatsi
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - R Knobler
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - E Guenova
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - F Child
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the UK Cutaneous Lymphoma Group
| | - S Whittaker
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
- Member of the UK Cutaneous Lymphoma Group
| | - V Nikolaou
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - C Tomasini
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - I Amitay
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - H Prag Naveh
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - C Ram-Wolff
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - M Battistella
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - S Alberti-Violetti
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - R Stranzenbach
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - V Gargallo
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - C Muniesa
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - T Koletsa
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - C Jonak
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - S Porkert
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - C Mitteldorf
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - T Estrach
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - A Combalia
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - M Marschalko
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - J Csomor
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - A Szepesi
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - A Cozzio
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - R Dummer
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - N Pimpinelli
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - V Grandi
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - M Beylot-Barry
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - A Pham-Ledard
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - M Wobser
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - E Geissinger
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - U Wehkamp
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - M Weichenthal
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - R Cowan
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the UK Cutaneous Lymphoma Group
| | - E Parry
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the UK Cutaneous Lymphoma Group
| | - J Harris
- Member of the UK Cutaneous Lymphoma Group
| | - R Wachsmuth
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the UK Cutaneous Lymphoma Group
| | - D Turner
- Member of the UK Cutaneous Lymphoma Group
| | - A Bates
- Member of the UK Cutaneous Lymphoma Group
| | - E Healy
- Member of the UK Cutaneous Lymphoma Group
| | - F Trautinger
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - J Latzka
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - J Yoo
- European Co-ordinating PROCLIPI Centre for PROCLIPI, University Hospitals Birmingham, Birmingham, U.K
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - B Vydianath
- European Co-ordinating PROCLIPI Centre for PROCLIPI, University Hospitals Birmingham, Birmingham, U.K
| | - R Amel-Kashipaz
- European Co-ordinating PROCLIPI Centre for PROCLIPI, University Hospitals Birmingham, Birmingham, U.K
| | - L Marinos
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - A Oikonomidi
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - A Stratigos
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - M-D Vignon-Pennamen
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - M Battistella
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - F Climent
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - E Gonzalez-Barca
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - E Georgiou
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - R Senetta
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - P Zinzani
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - L Vakeva
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - A Ranki
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - A-M Busschots
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - E Hauben
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - A Bervoets
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - F J S H Woei-A-Jin
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - R Matin
- Member of the UK Cutaneous Lymphoma Group
| | - G Collins
- Member of the UK Cutaneous Lymphoma Group
| | | | - J Frew
- Member of the UK Cutaneous Lymphoma Group
| | - M Bayne
- Member of the UK Cutaneous Lymphoma Group
| | - G Dunnill
- Member of the UK Cutaneous Lymphoma Group
| | - P McKay
- Member of the UK Cutaneous Lymphoma Group
| | | | - R Azurdia
- Member of the UK Cutaneous Lymphoma Group
| | - K Benstead
- Member of the UK Cutaneous Lymphoma Group
| | - R Twigger
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - K Rieger
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - R Brown
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - J A Sanches
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - D Miyashiro
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - O Akilov
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - S McCann
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - H Sahi
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - F M Damasco
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - C Querfeld
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - A Folkes
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - C Bur
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - C-D Klemke
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - P Enz
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - R Pujol
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - K Quint
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - L Geskin
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - E Hong
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - F Evison
- European Co-ordinating PROCLIPI Centre for PROCLIPI, University Hospitals Birmingham, Birmingham, U.K
| | - M Vermeer
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - L Cerroni
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - W Kempf
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - Y Kim
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - R Willemze
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| |
Collapse
|
4
|
Salles G, Duell J, González Barca E, Jurczak W, Liberati A, Nagy Z, Obr A, Gaidano G, Andre M, Kalakonda N, Dreyling M, Zinzani P, Dirnberger-Hertweck M, Weirather J, Ambarkhane S, Maddocks K. PRIMARY ANALYSIS RESULTS OF THE SINGLE-ARM PHASE II STUDY OF MOR208 PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (L-MIND). Hematol Oncol 2019. [DOI: 10.1002/hon.130_2629] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- G. Salles
- Hospices Civils de Lyon; Centre Hospitalier Lyon Sud, Service d'Hématologie; Pierre-Bénite France
| | - J. Duell
- Medizinische Klinik und Poliklinik II; University Hospital of Würzburg; Würzburg Germany
| | - E. González Barca
- Department of Hematology; Institut Catalá d'Oncología, Hospital Duran i Reynals, IDIBELL; Barcelona Spain
| | - W. Jurczak
- Department of Hematology; Jagiellonian University; Kraków Poland
| | - A.M. Liberati
- SC Oncoematologia; Azienda Ospedaliera Santa Maria; Terni Italy
| | - Z. Nagy
- First Department of Internal Medicine; Semmelweis University; Budapest Hungary
| | - A. Obr
- Department of Hemato-Oncology; Palacký University Olomouc and the University Hospital Olomouc; Olomouc Czech Republic
| | - G. Gaidano
- Division of Haematology; Department of Translational Medicine, University of Eastern Piedmont; Novara Italy
| | - M. Andre
- Department of Hematology; Université catholique de Louvain, CHU UCL Namur; Yvoir Belgium
| | - N. Kalakonda
- Department of Haemato-oncology; Clatterbridge Cancer Centre and University of Liverpool; Wirral United Kingdom
| | - M. Dreyling
- Department of Medicine III; University Hospital of Ludwig-Maximilians-Universität; Munich Germany
| | - P.L. Zinzani
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| | | | - J. Weirather
- Department of Biostatistics and Data Management; MorphoSys AG; Planneg Germany
| | - S. Ambarkhane
- Department of Clinical Development; MorphoSys AG; Planegg Germany
| | - K. Maddocks
- Department of Internal Medicine; Division of Hematology, The Ohio State University Comprehensive Cancer Center; Columbus Ohio United States
| |
Collapse
|
5
|
Zinzani P, Samaniego F, Jurczak W, Lech-Maranda E, Ghosh N, Anz B, Patten P, Reeves J, Leslie L, Smolewski P, Chavez J, Scarfo L, Derenzini E, Burke J, Sharman J, Kolibaba K, O'Connor O, Cheah C, Miskin H, Sportelli P, Weiss M, Fowler N. UMBRALISIB MONOTHERAPY DEMONSTRATES EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA: A MULTICENTER, OPEN-LABEL, REGISTRATION DIRECTED PHASE 2 STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.139_2629] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- P. Zinzani
- Institute of Hematology; "L. e A. Seragnoli" University of Bologna; Bologna Italy
| | - F. Samaniego
- Department of Lymphoma/ Myeloma; MD Anderson Cancer Center; Houston United States
| | - W. Jurczak
- Department of Hematology; Jagiellonian University; Krakow Poland
| | - E. Lech-Maranda
- Department of Hematology; Institute of Hematology and Transfusion Medicine; Warsaw Poland
| | - N. Ghosh
- Department of Hematologic Oncology and Blood Disorders; Levine Cancer Center; Charlotte United States
| | - B. Anz
- Tennessee Oncology; Sarah Cannon Research Institute; Chattanooga United States
| | - P. Patten
- Department of Hematology; Kings Hospital NHS Foundation Trust; London United Kingdom
| | - J. Reeves
- Florida Cancer Specialists; Sarah Cannon Research Institute; Fort Myers United States
| | - L.A. Leslie
- John Theurer Cancer Center; Hackensack University Medical Center; Hackensack United States
| | - P. Smolewski
- Department of Hematology; Copernicus Memorial Hospital; Lodz Poland
| | - J.C. Chavez
- Department of Hematology; H. Lee Moffitt Cancer Center and Research Institute; Tampa United States
| | - L. Scarfo
- IRCCS Ospedale San Raffaele; Università Vita-Salute San Raffaele; Milan Italy
| | - E. Derenzini
- Department of Hematology; European Institute of Oncology; Milan Italy
| | - J.M. Burke
- Rocky Mountain Cancer Centers; US Oncology; Aurora United States
| | - J. Sharman
- Willamette Valley Cancer Institute; US Oncology; Eugene United States
| | - K. Kolibaba
- Compass Oncology; US Oncology; Vancouver United States
| | - O.A. O'Connor
- Center for Lymphoid Malignancies; Columbia University Medical Center; New York United States
| | - C.Y. Cheah
- Department of Hematology; Sir Charles Gairdner Hospital; Perth Australia
| | - H.P. Miskin
- Drug Development; TG Therapeutics; New York United States
| | - P. Sportelli
- Drug Development; TG Therapeutics; New York United States
| | - M.S. Weiss
- Drug Development; TG Therapeutics; New York United States
| | - N.H. Fowler
- Department of Lymphoma/ Myeloma; MD Anderson Cancer Center; Houston United States
| |
Collapse
|
6
|
Dreyling M, Santoro A, Leppä S, Demeter J, Follows G, Lenz G, Kim W, Mollica L, Nagler A, Phipps Diong C, Provencio M, Magagnoli M, Munoz J, Hiemeyer F, Liu L, Miriyala A, Rodrigues L, Garcia-Vargas J, Childs B, Zinzani P. EFFICACY AND SAFETY IN HIGH-RISK RELAPSED OR REFRACTORY INDOLENT FOLLICULAR LYMPHOMA PATIENTS TREATED WITH COPANLISIB. Hematol Oncol 2019. [DOI: 10.1002/hon.57_2631] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- M. Dreyling
- Department of Medicine III; University Hospital (LMU); Munich Germany
| | - A. Santoro
- Cancer Center; Humanitas Clinical and Research Center; Rozzano Italy
| | - S. Leppä
- Comprehensive Cancer Center; Helsinki University Hospital; Helsinki Finland
| | - J. Demeter
- First Department of Internal Medicine; Semmelweis University; Budapest Hungary
| | - G.A. Follows
- Haematology; Cambridge University Hospitals NHS Foundation Trust; Cambridge United Kingdom
| | - G. Lenz
- Translational Oncology; University Hospital Münster; Münster Germany
| | - W.S. Kim
- Hematology and Oncology; Sungkyunkwan University School of Medicine, Samsung Medical Center; Seoul Republic of Korea
| | - L. Mollica
- Clinical Research in Hematology and Clinical Oncology; Maisonneuve-Rosemont Hospital Research Centre; Montréal Quebec Canada
| | - A. Nagler
- Chaim Sheba Medical Center; Tel Aviv University; Tel HaShomer Israel
| | - C. Phipps Diong
- Department of Haematology; Singapore General Hospital; Bukit Merah Singapore
| | - M. Provencio
- Medical Oncology; Health Research Institute, Hospital Universitario Puerta de Hierro, Universidad Autónoma de Madrid; Madrid Spain
| | - M. Magagnoli
- Cancer Center; Humanitas Clinical and Research Center; Rozzano Italy
| | - J. Munoz
- Hematology and Oncology; Banner MD Anderson Cancer Center Clinic; Gilbert United States
| | - F. Hiemeyer
- Pharmaceutical Division; Bayer AG; Berlin Germany
| | - L. Liu
- Oncology; Bayer HealthCare Pharmaceuticals, Inc.; Whippany United States
| | - A. Miriyala
- Oncology; Bayer HealthCare Pharmaceuticals, Inc.; Whippany United States
| | | | - J. Garcia-Vargas
- Oncology; Bayer HealthCare Pharmaceuticals, Inc.; Whippany United States
| | - B.H. Childs
- Oncology; Bayer HealthCare Pharmaceuticals, Inc.; Whippany United States
| | - P.L. Zinzani
- Institute of Hematology “Seràgnoli”; University of Bologna; Bologna Italy
| |
Collapse
|
7
|
Zinzani P, Santoro A, Gritti G, Brice P, Barr P, Kuruvilla J, Cunningham D, Kline J, Johnson N, Mehta-Shah N, Manley T, Francis S, Sharma M, Moskowitz A. NIVOLUMAB COMBINED WITH BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: EFFICACY AND SAFETY FROM THE PHASE 2 CHECKMATE 436 STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.114_2629] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- P.L. Zinzani
- Institute of Hematology; “Seràgnoli" Bologna University; Bologna Italy
| | - A. Santoro
- Oncologia medica; Istituto Clinico Humanitas; Rozzano-Milano Italy
| | - G. Gritti
- Hematology and Bone Marrow Transplant Unit; Ospedale Papa Giovanni XXIII; Bergamo Italy
| | - P. Brice
- Service d'Hémato-Oncologie; Hôpital Saint-Louis; Paris France
| | - P.M. Barr
- Dept. of Hematology/Oncology; University of Rochester; Rochester United States
| | - J. Kuruvilla
- Division of Medical Oncology and Hematology; Princess Margaret Cancer Centre; Toronto Canada
| | - D. Cunningham
- Gastrointestinal and Lymphoma Unit; Royal Marsden Hospital; London United Kingdom
| | - J. Kline
- Hematology & Oncology (Cancer); University of Chicago; Chicago United States
| | - N.A. Johnson
- Division of Hematology; Jewish General Hospital; Montréal Canada
| | - N.A. Mehta-Shah
- Department of Oncology; Washington University School of Medicine; St Louis United States
| | - T. Manley
- Seattle Genetics; Bothell United States
| | - S. Francis
- Bristol-Myers Squibb; Princeton United States
| | - M. Sharma
- Bristol-Myers Squibb; Princeton United States
| | - A.J. Moskowitz
- Lymphoma Inpatient Unit; Memorial Sloan Kettering Cancer Center; New York United States
| |
Collapse
|
8
|
Tiacci E, De Carolis L, Simonetti E, Zaja F, Capponi M, Ambrosetti A, Lucia E, Antolino A, Pulsoni A, Ferrari S, Zinzani P, Rigacci L, Gaidano G, Della Seta R, Frattarelli N, Falcucci P, Visani G, Foà R, Falini B. THE BRAF INHIBITOR VEMURAFENIB PLUS RITUXIMAB PRODUCES A HIGH RATE OF DEEP AND DURABLE RESPONSES IN RELAPSED/REFRACTORY HAIRY CELL LEUKEMIA: UPDATED RESULTS OF A PHASE-2 TRIAL. Hematol Oncol 2019. [DOI: 10.1002/hon.72_2629] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- E. Tiacci
- Institute of Hematology and Center for Hemato-Oncology Research; University and Hospital of Perugia; Perugia Italy
| | - L. De Carolis
- Institute of Hematology and Center for Hemato-Oncology Research; University and Hospital of Perugia; Perugia Italy
| | - E. Simonetti
- Institute of Hematology and Center for Hemato-Oncology Research; University and Hospital of Perugia; Perugia Italy
| | - F. Zaja
- Hematology Unit; Azienda Sanitaria Universitaria Integrata-Ospedale Maggiore; Trieste Italy
| | - M. Capponi
- Institute of Hematology and Center for Hemato-Oncology Research; University and Hospital of Perugia; Perugia Italy
| | - A. Ambrosetti
- Department of Medicine; Section of Hematology; Verona Italy
| | - E. Lucia
- Hematology Unit; Ospedale di Cosenza; Cosenza Italy
| | - A. Antolino
- Hematology Unit, Department of Transfusional Medicine - SIMMT; Maria Paternò-Arezzo Hospital; Ragusa Italy
| | - A. Pulsoni
- Hematology Unit, Department of Translational and Precision Medicine; "Sapienza" University of Rome; Roma Italy
| | - S. Ferrari
- Department of Hematology; Spedali Civili di Brescia; Brescia Italy
| | - P. Zinzani
- Institute of Hematology, Policlinico Sant'Orsola-Malpighi; University of Bologna; Bologna Italy
| | - L. Rigacci
- Hematology and Stem Cell Transplant Unit; AO San Camillo Forlanini; Roma Italy
| | - G. Gaidano
- Department of Translational Medicine, Division of Hematology; Amedeo Avogadro University of Eastern Piedmont; Novara Italy
| | | | | | - P. Falcucci
- Hematology Unit; Ospedale di Ronciglione; Viterbo Italy
| | - G. Visani
- Hematology Unit; Ospedale di Pesaro; Pesaro Italy
| | - R. Foà
- Hematology Unit, Department of Translational and Precision Medicine; "Sapienza" University of Rome; Roma Italy
| | - B. Falini
- Institute of Hematology and Center for Hemato-Oncology Research; University and Hospital of Perugia; Perugia Italy
| |
Collapse
|
9
|
Horwitz S, Scarisbrick J, Prince H, Whittaker S, Duvic M, Kim Y, Quaglino P, Zinzani P, Bechter O, Eradat H, Pinter-Brown L, Akilov O, Geskin L, Sanches J, Ortiz-Romero P, Lisano J, Brown L, Palanca-Wessels M, Gautam A, Bunn V, Little M, Dummer R. FINAL DATA FROM THE PHASE 3 ALCANZA STUDY: BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN PATIENTS (PTS) WITH CD30-POSITIVE (CD30+) CUTANEOUS T-CELL LYMPHOMA (CTCL). Hematol Oncol 2019. [DOI: 10.1002/hon.96_2630] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- S.M. Horwitz
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York United States
| | - J. Scarisbrick
- Department of Dermatology; University Hospital Birmingham; Birmingham United Kingdom
| | - H.M. Prince
- Division of Cancer Medicine; Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, The University of Melbourne; Melbourne Australia
| | - S. Whittaker
- St John's Institute of Dermatology; Guys and St Thomas NHS Foundation Trust; London United Kingdom
| | - M. Duvic
- Department of Dermatology; Division of Internal Medicine, The University of Texas MD Anderson Cancer Center; Houston United States
| | - Y.H. Kim
- Department of Dermatology; Stanford University School of Medicine and Stanford Cancer Institute; Stanford United States
| | - P. Quaglino
- Department of Medical Sciences; Dermatologic Clinic, University of Turin; Turin Italy
| | - P.L. Zinzani
- Institute of Haematology; University of Bologna; Bologna Italy
| | - O. Bechter
- Department of General Medical Oncology; University Hospitals Leuven; Leuven KU Belgium
| | - H. Eradat
- Division of Hematology-Oncology; David Geffen School of Medicine at UCLA; Los Angeles United States
| | - L. Pinter-Brown
- Division of Hematology Oncology; Chao Family Comprehensive Cancer Center, University of California; Irvine United States
| | - O. Akilov
- Department of Dermatology; University of Pittsburgh; Pittsburgh United States
| | - L. Geskin
- Department of Dermatology; Columbia University; New York United States
| | - J. Sanches
- Department of Dermatology; University of São Paulo Medical School; São Paulo Brazil
| | - P. Ortiz-Romero
- Department of Dermatology; University Hospital 12 de Octubre, Institute i+12 Medical School, University Complutense; Madrid Spain
| | - J. Lisano
- Medical Affairs; Seattle Genetics, Inc.; Bothell United States
| | - L. Brown
- Biostatistics; Seattle Genetics, Inc.; Bothell United States
| | | | - A. Gautam
- Global Medical Affairs; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge United States
| | - V. Bunn
- Oncology Statistics; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge United States
| | - M. Little
- Oncology Clinical Research; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge United States
| | - R. Dummer
- Department of Dermatology; University Hospital Zürich; Zürich Switzerland
| |
Collapse
|
10
|
Jacobsen E, Ďuraš J, Ardeshna K, Cherry M, Offner F, Mayer J, Bijou F, Tani M, Musuraca G, Merli M, Marasca R, Weaver D, Lustgarten S, Youssoufian H, Zinzani P. CHARACTERIZATION OF DUVELISIB IN PATIENTS WITH REFRACTORY MARGINAL ZONE LYMPHOMA: DATA FROM THE PHASE 2 DYNAMO TRIAL. Hematol Oncol 2019. [DOI: 10.1002/hon.70_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- E. Jacobsen
- Department of Medical Oncology; Dana-Farber Cancer Institute; Boston MA United States
| | - J. Ďuraš
- University Hospital Ostrava and Faculty of Medicine; University Hospital Ostrava; Ostrava Czech Republic
| | - K. Ardeshna
- Department of Oncology; University College London Hospitals National Health Service Foundation Trust; London United Kingdom
| | - M. Cherry
- Department of Medical Oncology; Atlantic Health Systems; Morristown NJ United States
| | - F. Offner
- Department of Hematology; University Hospital Ghent; Gent Belgium
| | - J. Mayer
- Department of Internal Medicine; Fakultní Nemocnice Brno; Brno Czech Republic
| | - F. Bijou
- Department of Medical Oncology; Institut Bergonie; Boredeaux France
| | - M. Tani
- Hematology Unit; Santa Maria delle Croci Hospital; Ravenna Italy
| | - G. Musuraca
- Hematology Unit; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori; Meldola Italy
| | - M. Merli
- Department of Hematology; Ospedale di Circolo e Fondazione Macchi; Varese Italy
| | - R. Marasca
- Department of Medical Sciences; Section of Hematology, Università di Modena e Reggio Emilia; Modena Italy
| | - D.T. Weaver
- Medical Affairs; Verastem Oncology; Needham MA United States
| | - S. Lustgarten
- Medical Affairs; Verastem Oncology; Needham MA United States
| | - H. Youssoufian
- Medical Affairs; Verastem Oncology; Needham MA United States
| | - P. Zinzani
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| |
Collapse
|
11
|
Balasubramanian S, Wang S, Major C, Hodkinson B, Schaffer M, Sehn L, Johnson P, Zinzani P, Carey J, Liu G, Loefgren C, Shreeve M, Sun S, Zhuang S, Vermeulen J, Staudt L, Younes A, Wilson W. CONCORDANCE BETWEEN IMMUNOHISTOCHEMISTRY AND GENE EXPRESSION PROFILING SUBTYPING FOR DIFFUSE LARGE B-CELL LYMPHOMA IN THE PHASE 3 PHOENIX TRIAL. Hematol Oncol 2019. [DOI: 10.1002/hon.99_2629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- S. Balasubramanian
- Clinical Oncology; Janssen Research & Development, San Diego, CA, USA; San Diego United States
| | - S. Wang
- Clinical Oncology; Janssen Research & Development, Raritan, NJ, USA; Raritan United States
| | - C. Major
- Oncology Translational Research; Janssen Research & Development, Spring House, PA, USA; Spring House United States
| | - B. Hodkinson
- Oncology Translational Research; Janssen Research & Development, Spring House, PA, USA; Spring House United States
| | - M. Schaffer
- Oncology Translational Research; Janssen Research & Development, Spring House, PA, USA; Spring House United States
| | - L.H. Sehn
- BC Cancer Centre; BC Cancer Centre for Lymphoid Cancer; Vancouver Canada
| | - P. Johnson
- Cancer Research UK Clinical Centre; University of Southampton; Southampton United Kingdom
| | - P.L. Zinzani
- Institute of Hematology; “Seràgnoli” University of Bologna; Bologna Italy
| | - J. Carey
- Clinical Oncology; Janssen Research & Development, Spring House, PA, USA; Spring House United States
| | - G. Liu
- Clinical Oncology; Janssen Research & Development, Raritan, NJ, USA; Raritan United States
| | - C. Loefgren
- Clinical Oncology; Janssen Research & Development, Raritan, NJ, USA; Raritan United States
| | - M. Shreeve
- Clinical Oncology; Janssen Research & Development, San Diego, CA, USA; San Diego United States
| | - S. Sun
- Clinical Oncology; Janssen Research & Development, Raritan, NJ, USA; Raritan United States
| | - S. Zhuang
- Clinical Oncology; Janssen Research & Development, Raritan, NJ, USA; Raritan United States
| | - J. Vermeulen
- Clinical Oncology; Janssen Research & Development; Leiden Netherlands
| | - L.M. Staudt
- Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute; National Institutes of Health; Bethesda United States
| | - A. Younes
- Lymphoma Service; Memorial Sloan Kettering Cancer Center; New York United States
| | - W. Wilson
- National Cancer Institute; National Institutes of Health; Bethesda United States
| |
Collapse
|
12
|
Scarisbrick J, Geskin L, Bagot M, Fisher D, Elmets C, Duvic M, Beylot-Barry M, Kim E, Moriya J, Leoni M, Zinzani P. EFFICACY OF MOGAMULIZUMAB IN PREVIOUSLY TREATED PATIENTS WITH LESS ADVANCED MYCOSIS FUNGOIDES: RESULTS FROM THE MAVORIC STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.34_2629] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- J. Scarisbrick
- Lymphoma Service; University Hospital Birmingham; Birmingham United Kingdom
| | - L.J. Geskin
- Dermatology; Columbia University Medical Center; New York United States
| | - M. Bagot
- Service de Dermatologie; Hôpital Saint Louis, APHP, Inserm U976, Université Paris 7; Paris France
| | - D.C. Fisher
- Hematologic Oncology; Dana-Farber Cancer Institute; Boston United States
| | - C. Elmets
- Dermatology; University of Alabama at Birmingham; Birmingham United States
| | - M. Duvic
- Dermatology; University of Texas MD Anderson Cancer Center; Houston United States
| | - M. Beylot-Barry
- Service de Dermatologie; CHU de Bordeaux - Hôpital Saint-André; Bordeaux France
| | - E.J. Kim
- Dermatology; University of Pennsylvania; Philadelphia United States
| | - J. Moriya
- Biostatistics; Kyowa Kirin Pharmaceutical Development, Inc.; Princeton United States
| | - M. Leoni
- Medical Sciences; Kyowa Kirin Pharmaceutical Development, Inc.; Princeton United States
| | - P.L. Zinzani
- Istituto di Ematologia; Università di Bologna; Bologna Italy
| |
Collapse
|
13
|
Panayiotidis P, Kellner A, Follows G, Mollica L, Nagler A, Özcan M, Santoro A, Hiemeyer F, Liu L, Garcia-Vargas J, Childs B, Zinzani P, Dreyling M. COPANLISIB TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.69_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- P. Panayiotidis
- School of Medicine; National and Kapodistrian University of Athens; Athens Greece
| | - A. Kellner
- Hematology; Kaposi Mór Teaching Hospital; Kaposvár Hungary
| | - G.A. Follows
- Haematology; Cambridge University Hospitals NHS Foundation Trust; Cambridge United Kingdom
| | - L. Mollica
- Clinical Research in Hematology and Clinical Oncology; Maisonneuve-Rosemont Hospital Research Centre; Montréal Quebec Canada
| | - A. Nagler
- Chaim Sheba Medical Center; Tel Aviv University; Tel HaShomer Israel
| | - M. Özcan
- Hematology; Ankara University; Ankara Turkey
| | - A. Santoro
- Cancer Center; Humanitas Clinical and Research Center; Rozzano Italy
| | - F. Hiemeyer
- Pharmaceutical Division; Bayer AG; Berlin Germany
| | - L. Liu
- Oncology; Bayer HealthCare Pharmaceuticals, Inc.; Whippany United States
| | - J. Garcia-Vargas
- Oncology; Bayer HealthCare Pharmaceuticals, Inc.; Whippany United States
| | - B.H. Childs
- Oncology; Bayer HealthCare Pharmaceuticals, Inc.; Whippany United States
| | - P.L. Zinzani
- Institute of Hematology "Seràgnoli"; University of Bologna; Bologna Italy
| | - M. Dreyling
- Department of Medicine III; University Hospital (LMU); Munich Germany
| |
Collapse
|
14
|
Zinzani P, Turner D, Marshall S, Conteh V, Kang H, Kim S, Lee Y, Bishton M. REAL WORLD EFFECTIVENESS AND SAFETY OF CT-P10 IN DIFFUSE LARGE B-CELL LYMPHOMA: INTERIM RESULTS FROM A EUROPEAN NON-INTERVENTIONAL POST-AUTHORISATION SAFETY STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.121_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- P. Zinzani
- Institute of Hematology “Seràgnoli”; University of Bologna; Bologna Italy
| | - D.L. Turner
- Department of Haematology; Torbay and South Devon NHS Foundation Trust; Torquay United Kingdom
| | - S.R. Marshall
- Department of Haematology; Sunderland Royal Hospital, City Hospitals Sunderland NHS Trust; Sunderland United Kingdom
| | - V. Conteh
- Cancer Services; Royal Free London NHS Foundation Trust, Barnet Hospital; Barnet United Kingdom
| | - H. Kang
- Medical Affairs; Celltrion Healthcare; Incheon Republic of Korea
| | - S. Kim
- Medical Affairs; Celltrion Healthcare; Incheon Republic of Korea
| | - Y. Lee
- Medical Affairs; Celltrion Healthcare; Incheon Republic of Korea
| | - M.J. Bishton
- Department of Haematology; Nottingham City Hospital; Nottingham United Kingdom
| |
Collapse
|
15
|
Awan F, Chan R, Gu L, Xing G, Bhargava P, Ruzicka B, Dreyling M, Zinzani P, Gopal A. TREATMENT EMERGENT ADVERSE EVENTS VARY WITH DIFFERENT PI3K INHIBITORS. Hematol Oncol 2019. [DOI: 10.1002/hon.208_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- F.T. Awan
- Harold C. Simmons Comprehensive Cancer Center; University of Texas Southwestern Medical Center; Dallas United States
| | - R.J. Chan
- Medical Affairs; Gilead Sciences, Inc.; Foster City United States
| | - L. Gu
- Biostatistics; Gilead Sciences, Inc.; Seattle United States
| | - G. Xing
- Biostatistics; Gilead Sciences, Inc.; Seattle United States
| | - P. Bhargava
- Medical Affairs; Gilead Sciences, Inc.; Foster City United States
| | - B. Ruzicka
- Medical Affairs; Gilead Sciences, Inc.; Foster City United States
| | - M. Dreyling
- Department of Medicine III; University Hospital of the Ludwig Maximilians University Munich; München Germany
| | - P. Zinzani
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| | - A.K. Gopal
- Fred Hutchinson Cancer Research Center; Seattle Cancer Care Alliance, University of Washington; Seattle United States
| |
Collapse
|
16
|
Zelenetz A, Zinzani P, Buske C, Ribrag V, Cunningham D, Jurczak W, Abrisqueta P, Agajanian R, Chaudhry A, Kayyal T, Wood J, Llorin-Sangalang J, Brown J. A PIVOTAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, TWO-ARM, PHASE 2 STUDY OF ME-401 INVESTIGATING TWO DOSING SCHEDULES IN PATIENTS WITH FOLLICULAR LYMPHOMA (FL) AFTER FAILURE OF TWO OR MORE PRIOR SYSTEMIC THERAPIES. Hematol Oncol 2019. [DOI: 10.1002/hon.2_2632] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- A. Zelenetz
- Lymphoma Service; Memorial Sloan Kettering Cancer Center; New York United States
| | - P. Zinzani
- Institute of Hematology; University of Bologna; Bologna Italy
| | - C. Buske
- Life Science Gebaeude; Universitatklinikum Ulm; Ulm Germany
| | - V. Ribrag
- Gustave Roussy Cancer Center; Institut Gustave Roussy; Villejuif France
| | - D. Cunningham
- Lymphoma Unit; Royal Marsden Hospital NHS; Sutton United Kingdom
| | - W. Jurczak
- Department of Hematology; Jagiellonian University; Kraków Poland
| | - P. Abrisqueta
- Department of Hematology; Hospital Vall Hebron; Barcelona Spain
| | - R. Agajanian
- Department of Hematology; The Oncology Institute of Hope and Innovation; Cerritos United States
| | - A. Chaudhry
- Medical Oncology/Hematology; Medical Oncology Associates PS; Spokane United States
| | - T. Kayyal
- Department of Oncology/Hematology; Renovatio Clinical; The Woodlands United States
| | - J. Wood
- Medical Affairs; MEI Pharma, Inc.; San Diego United States
| | | | - J. Brown
- Division of Hematologic Malignancies; Dana Farber Cancer Institute; Boston United States
| |
Collapse
|
17
|
Marangon M, Morigi A, Casadei B, Broccoli A, Nanni L, Stefoni V, Argnani L, Lolli G, Carella M, Zinzani P. 90
Y-IBRITUMOMAB TIUXETAN IN PATIENTS WITH EXTRA-NODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA ASSOCIATED LYMPHOID TISSUE (MALT LYMPHOMA) - THE ZENO STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.72_2630] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- M. Marangon
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| | - A. Morigi
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| | - B. Casadei
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| | - A. Broccoli
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| | - L. Nanni
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| | - V. Stefoni
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| | - L. Argnani
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| | - G. Lolli
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| | - M. Carella
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| | - P. Zinzani
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| |
Collapse
|
18
|
Bishton M, Marshall S, Conteh V, Rodríguez Fernández A, Kang H, Kim S, Lee Y, Zinzani P. CT-P10 RAPID INFUSION IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA OR CHRONIC LYMPHOCYTIC LEUKAEMIA: INTERIM RESULTS FROM A NON-INTERVENTIONAL POST-AUTHORISATION SAFETY STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.224_2631] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- M. Bishton
- Department of Haematology; City Hospital Nottingham; Nottingham United Kingdom
| | - S.R. Marshall
- Department of Haematology; Sunderland Royal Hospital, City Hospitals Sunderland NHS Trust; Sunderland United Kingdom
| | - V. Conteh
- Cancer Services; Royal Free London NHS Foundation Trust, Barnet Hospital; Barnet United Kingdom
| | | | - H. Kang
- Medical Affairs; Celltrion Healthcare; Incheon Republic of Korea
| | - S. Kim
- Medical Affairs; Celltrion Healthcare; Incheon Republic of Korea
| | - Y. Lee
- Medical Affairs; Celltrion Healthcare; Incheon Republic of Korea
| | - P. Zinzani
- Institute of Hematology “Seràgnoli”; University of Bologna; Bologna Italy
| |
Collapse
|
19
|
Wang M, Belada D, Cheah C, Chu M, Dreyling M, Flinn I, Fogliatto L, Goy A, Inwards D, Jurczak W, Mayer J, Re F, Robak T, Spurgeon S, Yoon S, Zinzani P, Yin M, Chen T, Kahl B. A PHASE 3 STUDY OF ACALABRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN ELDERLY (AGED ≥65 Years) TREATMENT-NAIVE PATIENTS WITH MANTLE CELL LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.2632] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- M. Wang
- Department of Lymphoma/Myeloma; The University of Texas MD Anderson Cancer Center; Houston United States
| | - D. Belada
- Charles University Hospital and Faculty of Medicine; Fourth Department of Internal Medicine-Hematology; Hradec Králové Czech Republic
| | - C. Cheah
- Comprehensive Cancer Centre; Sir Charles Gairdner Hospital; Nedlands WA Australia
| | - M.P. Chu
- Clinician Scientist; Cross Cancer Institute; Edmonton Canada
| | - M. Dreyling
- Medizinische Klinik und Poliklinik III; Klinikum der Universität München, LMU München; München Germany
| | - I. Flinn
- Lymphoma Research; Sarah Cannon; Nashville United States
| | - L. Fogliatto
- Hematology; Irmandade da Santa Case de Misericórdia; Porto Alegre Brazil
| | - A. Goy
- Lymphoma Division; John Theurer Cancer Center, Hackensack University Medical Center; Hackensack United States
| | - D. Inwards
- Hematology; Mayo Clinic; Rochester United States
| | - W. Jurczak
- Department of Hematology; Jagiellonian University; Krakow Poland
| | - J. Mayer
- Hematology; Fakultní nemocnice Brno; Brno Czech Republic
| | - F. Re
- Hematology; Azienda Ospedaliero-Universitaria di Parma; Parma Italy
| | - T. Robak
- Hematology; Medical University of Lodz, Copernicus Memorial Hospital; Lodz Poland
| | - S. Spurgeon
- Hematology and Medical Oncology; OHSU Knight Cancer Institute; Portland United States
| | - S.S. Yoon
- Hemato Oncology; Seoul National University Hospital; Seoul Republic of Korea
| | - P.L. Zinzani
- Hematology; Institute of Hematology Seràgnoli, University of Bologna; Bologna Italy
| | - M. Yin
- Bio statistics; Acerta Pharma; South San Francisco United States
| | - T. Chen
- Clinical Development; Acerta Pharma; South San Francisco United States
| | | | | |
Collapse
|
20
|
Zinzani P, Santoro A, Leppä S, Demeter J, Follows G, Lenz G, Kim W, Mollica L, Nagler A, Phipps Diong C, Provencio M, Magagnoli M, Munoz J, Miriyala A, Liu L, Zhang M, Garcia-Vargas J, Childs B, Dreyling M. SAFETY ANALYSIS OF PATIENTS WITH A MEDICAL HISTORY OF RESPIRATORY DISORDERS TREATED WITH COPANLISIB FROM THE CHRONOS-1 STUDY IN RELAPSED OR REFRACTORY INDOLENT B-CELL LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.58_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- P.L. Zinzani
- Institute of Hematology “Seràgnoli”; University of Bologna; Bologna Italy
| | - A. Santoro
- Cancer Center; Humanitas Clinical and Research Center; Rozzano Italy
| | - S. Leppä
- Comprehensive Cancer Center; Helsinki University Hospital; Helsinki Finland
| | - J. Demeter
- First Department of Internal Medicine; Semmelweis University; Budapest Hungary
| | - G.A. Follows
- Haematology; Cambridge University Hospitals NHS Foundation Trust; Cambridge United Kingdom
| | - G. Lenz
- Translational Oncology; University Hospital Münster; Münster Germany
| | - W.S. Kim
- Samsung Medical Center; Sungkyunkwan University School of Medicine; Seoul Republic of Korea
| | - L. Mollica
- Clinical Research in Hematology and Clinical Oncology; Maisonneuve-Rosemont Hospital Research Centre; Montréal, Quebec Canada
| | - A. Nagler
- Chaim Sheba Medical Center; Tel Aviv University; Tel HaShomer Israel
| | - C. Phipps Diong
- Department of Haematology; Singapore General Hospital; Bukit Merah Singapore
| | - M. Provencio
- Health Research Institute; Hospital Universitario Puerta de Hierro, Universidad Autónoma de Madrid; Madrid Spain
| | - M. Magagnoli
- Cancer Center; Humanitas Clinical and Research Center; Rozzano Italy
| | - J. Munoz
- Hematology and Oncology; Banner MD Anderson Cancer Center Clinic; Gilbert United States
| | - A. Miriyala
- Oncology; Bayer HealthCare Pharmaceuticals, Inc.; Whippany United States
| | - L. Liu
- Oncology; Bayer HealthCare Pharmaceuticals, Inc.; Whippany United States
| | - M. Zhang
- Oncology; Bayer HealthCare Pharmaceuticals, Inc.; Whippany United States
| | - J. Garcia-Vargas
- Oncology; Bayer HealthCare Pharmaceuticals, Inc.; Whippany United States
| | - B.H. Childs
- Oncology; Bayer HealthCare Pharmaceuticals, Inc.; Whippany United States
| | - M. Dreyling
- Department of Medicine III; University Hospital (LMU); Munich Germany
| |
Collapse
|
21
|
Porcu P, Kim Y, Zinzani P, Sicard H, Azim H, Bagot M. TELLOMAK: T-CELL LYMPHOMA ANTI-KIR3DL2 THERAPY: AN OPEN LABEL, MULTI-COHORT, MULTI-CENTER, INTERNATIONAL PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF IPH4102 ALONE OR IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH ADVANCED T-CELL LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.40_2629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- P. Porcu
- Medical Oncology; Sidney Kimmel Cancer Center, Thomas Jefferson University; Philadelphia United States
| | - Y. Kim
- Dermatology; Stanford Cancer Institute; San Francisco United States
| | - P. Zinzani
- Hematology/Oncology; University of Bologna; Bologna Italy
| | - H. Sicard
- Research and Development; Innate Pharma; Marseille France
| | - H.A. Azim
- Research and Development; Innate Pharma; Marseille France
| | - M. Bagot
- Dermatology; Hôpital Saint Louis; Paris France
| |
Collapse
|
22
|
Zinzani P, Armand P, Ribrag V, Michot J, Kuruvilla J, Zhu Y, Farooqui M, Nahar A, Moskowitz C. PHASE 1B KEYNOTE-013 STUDY OF PEMBROLIZUMAB IN PATIENTS WITH CLASSIC HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE: RESULTS OF >4 YEARS OF FOLLOW-UP. Hematol Oncol 2019. [DOI: 10.1002/hon.106_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- P.L. Zinzani
- Oncology; Institute of Hematology, University of Bologna; Bologna Italy
| | - P. Armand
- Medical Oncology; Dana-Farber Cancer Institute, Boston; United States
| | - V. Ribrag
- Medical Oncology; Institut Gustave Roussy, Villejuif; France
| | - J. Michot
- Medical Oncology; Institut Gustave Roussy, Villejuif; France
| | - J. Kuruvilla
- Medical Oncology and Hematology; Princess Margaret Cancer Centre and University of Toronto; Toronto Canada
| | - Y. Zhu
- Medical Oncology; Merck & Co, Inc.; Kenilworth United States
| | - M. Farooqui
- Medical Oncology; Merck & Co, Inc.; Kenilworth United States
| | - A. Nahar
- Medical Oncology; Merck & Co, Inc.; Kenilworth United States
| | - C.H. Moskowitz
- Medicine; University of Miami Sylvester Comprehensive Cancer Center; Miami United States
| |
Collapse
|
23
|
Illidge T, Horwitz S, Iyer S, Bartlett N, Kim W, Tilly H, Belada D, Feldman T, Illés Á, Jacobsen E, Hüttmann A, Zinzani P, O'Connor O, Trepicchio W, Miao H, Rao S, Onsum M, Manley T, Advani R. RESPONSE TO A+CHP BY CD30 EXPRESSION IN THE ECHELON-2 TRIAL. Hematol Oncol 2019. [DOI: 10.1002/hon.92_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- T. Illidge
- Division of Cancer Sciences, Faculty of Biology, Medicine and Health; University of Manchester, National Institutes of Health and Research Biomedical Research Centre, Manchester Academic Health Sciences Centre, Christie Hospital National Health Service Foundation Trust; Manchester United Kingdom
| | - S. Horwitz
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - S. Iyer
- Department of Lymphoma and Myeloma; Division of Cancer Medicine, MD Anderson Cancer Center; Houston United States
| | - N. Bartlett
- Department of Medicine; Oncology Division, Washington University School of Medicine, Siteman Cancer Center; Saint Louis United States
| | - W. Kim
- Division of Hematology-Oncology; Department of Medicine, Samsung Medical Center; Seoul Republic of Korea
| | - H. Tilly
- Department of Hematology; Centre Henri Becquerel, Université of Rouen Normandie; Rouen France
| | - D. Belada
- 4th Department of Internal Medicine - Haematology; Charles University, Hospital and Faculty of Medicine; Hradec Králové Czech Republic
| | - T. Feldman
- Hematology Division; Hackensack University Medical Center; Hackensack United States
| | - Á. Illés
- Department of Hematology; University of Debrecen, Faculty of Medicine; Debrecen Hungary
| | - E. Jacobsen
- Division of Hematologic Malignancies; Dana-Farber Cancer Institute; Boston United States
| | - A. Hüttmann
- Department of Haematology; Universitatsklinikum Essen; Essen Germany
| | - P. Zinzani
- Institute of Hematology; “Seràgnoli” University of Bologna; Bologna France
| | - O.A. O'Connor
- Department of Medicine; Columbia University Medical Center; New York United States
| | - W. Trepicchio
- Clinical Development; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceuticals Limited; Cambridge United States
| | - H. Miao
- Clinical Development; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceuticals Limited; Cambridge United States
| | - S. Rao
- Development; Seattle Genetics, Inc.; Bothell United States
| | - M. Onsum
- Development; Seattle Genetics, Inc.; Bothell United States
| | - T. Manley
- Development; Seattle Genetics, Inc.; Bothell United States
| | - R. Advani
- Medicine - Med/Oncology; Stanford Cancer Institute; Stanford United States
| |
Collapse
|
24
|
Pileri A, Starace M, Alessandrini A, Casadei B, Zinzani P, Piraccini B. New therapies and old side‐effects in mycosis fungoides treatment: brentuximab vedotin‐induced alopecia. Br J Dermatol 2019; 180:1535-1536. [DOI: 10.1111/bjd.17533] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- A. Pileri
- Dermatology Unit Department of Experimental Diagnostic and Speciality Medicine University of Bologna Via Massarenti 1 Bologna Italy
| | - M. Starace
- Dermatology Unit Department of Experimental Diagnostic and Speciality Medicine University of Bologna Via Massarenti 1 Bologna Italy
| | - A. Alessandrini
- Dermatology Unit Department of Experimental Diagnostic and Speciality Medicine University of Bologna Via Massarenti 1 Bologna Italy
| | - B. Casadei
- Hematology Unit Department of Experimental, Diagnostic and Speciality Medicine University of Bologna Via Massarenti 9 Bologna Italy
| | - P.L. Zinzani
- Hematology Unit Department of Experimental, Diagnostic and Speciality Medicine University of Bologna Via Massarenti 9 Bologna Italy
| | - B.M. Piraccini
- Dermatology Unit Department of Experimental Diagnostic and Speciality Medicine University of Bologna Via Massarenti 1 Bologna Italy
| |
Collapse
|
25
|
Stefoni V, Broccoli A, Botto B, Corradini P, Pinto A, Re A, Vitolo U, Fanti S, Argnani L, Zinzani P. FIRST SALVAGE TREATMENT WITH BENDAMUSTINE AND BRENTUXIMAB VEDOTIN IN HODGKIN LYMPHOMA: A PHASE 2 STUDY OF FIL ONLUS. Hematol Oncol 2019. [DOI: 10.1002/hon.105_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- V. Stefoni
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| | - A. Broccoli
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| | - B. Botto
- Hematology; Department of Oncology, University Hospital Città della Salute e della Scienza; Turin Italy
| | - P. Corradini
- IRCCS Istituto Nazionale dei Tumori; University of Milano; Milan Italy
| | - A. Pinto
- Hematology-Oncology and Stem Cell Transplantation Unit; National Cancer Institute, Fondazione Pascale; Naples Italy
| | - A. Re
- Hematology; Azienda socio-sanitaria territoriale, Ospedali Civili di Brescia; Brescia Italy
| | - U. Vitolo
- Hematology; Department of Oncology, University Hospital Città della Salute e della Scienza; Turin Italy
| | - S. Fanti
- Nuclear Medicine; Medicina Nucleare Metropolitana, Sant'Orsola-Malpighi Hospital, University of Bologna; Bologna Italy
| | - L. Argnani
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| | - P. Zinzani
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| |
Collapse
|
26
|
Bruscaggin A, Mollejo M, Tapia G, Gomes da Silva M, Novak U, Dietrich S, Ponzoni M, Rambaldi A, Corradini P, Vitolo U, Merli M, Tzankov A, Cogliatti S, Montalban C, Marasca R, de Leval L, Visco C, Baptista M, Tousseyn T, Facchetti F, Paulli M, Mazzucchelli L, Bea S, Oscier D, Zinzani P, Bhagat G, Inghirami G, Gaidano G, Traverse-Glehen A, Thieblemont C, Piris M, Cavalli F, Arcaini L, Zucca E, Rossi D. MULTI-OMICS LANDSCAPE OF SPLENIC MARGINAL ZONE LYMPHOMA (SMZL) - INTERIM ANALYSIS OF IELSG46 STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.138_2629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
27
|
Pinto A, De Filippi R, Zinzani P, Driessen C, Tun H, Hilgier K, Remmy D, Mehrling T, O'Connor O. A FIRST-IN-HUMAN TRIAL OF THE NOVEL MULTI-ACTION THERAPY TINOSTAMUSTINE (EDO-S101) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) HODGKIN LYMPHOMA (HL). Hematol Oncol 2019. [DOI: 10.1002/hon.137_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- A. Pinto
- Department of Hematology; University Federico II; Naples Italy
| | - R. De Filippi
- Department of Clinical Medicine and Surgery; University Federico II; Naples Italy
| | - P. Zinzani
- Department of Experimental; Diagnostic and Specialty Medicine, University of Bologna; Bologna Italy
| | - C. Driessen
- Interdisziplinäre Medizinische Dienste; Kantonsspital St Gallen; St Gallen Switzerland
| | - H.W. Tun
- Department of Hematology/Oncology; Mayo Clinic Cancer Center; Jacksonville United States
| | - K. Hilgier
- Clinical Development; Mundipharma EDO; Basel Switzerland
| | - D. Remmy
- Clinical Development; Mundipharma EDO; Basel Switzerland
| | - T. Mehrling
- Clinical Development; Mundipharma EDO; Basel Switzerland
| | - O.A. O'Connor
- Department of Medicine; Colombia University Medical Center; New York United States
| |
Collapse
|
28
|
Ricardi U, Levis M, Evangelista A, Gioia D, Rigacci L, Botto B, Simontacchi G, Franzone P, Rossi G, Buglione M, Pavone V, Bonfichi M, Rusconi C, Freilone R, Pulsoni A, De Sanctis V, Gaidano G, Stelitano C, Tani M, Castagnoli A, Ciccone G, Zaja F, Santoro A, Zinzani P. OC-0502 Role of consolidation RT to bulky lesions of advanced Hodgkin lymphoma: results of FIL HD0801 trial. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)30922-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
29
|
Scarisbrick J, Geskin L, Bagot M, Fisher D, Elmets C, Duvic M, Beylot-Barry M, Kim E, Moriya J, Leoni M, Zinzani P. Efficacy of mogamulizumab in previously treated patients with less advanced mycosis fungoides (MF): results from the MAVORIC study. Eur J Cancer 2019. [DOI: 10.1016/s0959-8049(19)30596-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
30
|
Zinzani P, Santoro A, Mollica L, Follows G, Bouabdallah K, Morschhauser F, Patnaik A, Huang L, Hiemeyer F, Benson A, Genvresse I, Garcia-Vargas J, Childs B, Dreyling M. Copanlisib monotherapy activity in relapsed or refractory indolent B-cell lymphoma: Combined analysis from phase I and II studies. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy286.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
31
|
Jurczak W, Rule S, Townsend W, Tucker D, Sarholz B, Scheele J, Gribben J, Zinzani P. Phase I/II, first in human trial with M7583, a Bruton’s tyrosine kinase inhibitor (BTKi), in patients with B cell malignancies. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy286.010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
32
|
Pileri A, Agostinelli C, Fuligni F, Broccoli A, Gunnella S, Sabattini E, Grandi V, Guglielmo A, Zinzani P, Patrizi A, Pimpinelli N. Primary cutaneous peripheral T-cell lymphoma not otherwise specified a rare and aggressive lymphoma. J Eur Acad Dermatol Venereol 2018; 32:e373-e376. [DOI: 10.1111/jdv.14942] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- A. Pileri
- Department of Experimental, Diagnostic and Specialty Medicine; Dermatology Unit; University of Bologna; Bologna Italy
- Department of Surgery and Translational Medicine; Dermatology Unit; University of Florence Medical School; Florence Italy
| | - C. Agostinelli
- Department of Experimental, Diagnostic and Specialty Medicine; Haematopathology Unit; University of Bologna; Bologna Italy
| | - F. Fuligni
- Department of Genetics and Genome Biology; The Hospital for Sick Children; Toronto Canada
| | - A. Broccoli
- Department of Experimental, Diagnostic and Specialty Medicine; Haematology Unit; University of Bologna; Bologna Italy
| | - S. Gunnella
- Department of Surgery and Translational Medicine; Dermatology Unit; University of Florence Medical School; Florence Italy
| | - E. Sabattini
- Department of Experimental, Diagnostic and Specialty Medicine; Haematopathology Unit; University of Bologna; Bologna Italy
| | - V. Grandi
- Department of Surgery and Translational Medicine; Dermatology Unit; University of Florence Medical School; Florence Italy
| | - A. Guglielmo
- Department of Experimental, Diagnostic and Specialty Medicine; Dermatology Unit; University of Bologna; Bologna Italy
| | - P.L. Zinzani
- Department of Experimental, Diagnostic and Specialty Medicine; Haematology Unit; University of Bologna; Bologna Italy
| | - A. Patrizi
- Department of Experimental, Diagnostic and Specialty Medicine; Dermatology Unit; University of Bologna; Bologna Italy
| | - N. Pimpinelli
- Department of Surgery and Translational Medicine; Dermatology Unit; University of Florence Medical School; Florence Italy
| |
Collapse
|
33
|
Michot JM, Bouabdallah R, Doorduijn J, Vitolo U, Kersten M, Chiappella A, Zinzani P, Pourdehnad M, Nikolova Z, Ribrag V. CC-122, a novel cereblon-modulating agent, in combination with obinutuzumab (GA101) in patients with relapsed and refractory (R/R) B-cell non-hodgkin lymphoma (NHL). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy048.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
34
|
Gerecitano J, Zheng H, Mongay Soler L, Ito R, Reis D, Lu C, Shen J, Childs B, Zinzani P. Phase III randomized, double-blind, controlled studies of the PI3K inhibitor copanlisib in combination with rituximab or rituximab-based chemotherapy in subjects with relapsed indolent B-cell non-Hodgkin’s lymphoma (iNHL): CHRONOS-3 and CHRONOS-4. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx373.040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
35
|
Provencio Pulla M, Santoro A, Mollica L, Leppä S, Follows G, Lenz G, Kim W, Nagler A, Panayiotidis P, Demeter J, Özcan M, Kosinova M, Bouabdallah K, Morschhauser F, Ishida T, Huang L, Garcia-Vargas J, Childs B, Zinzani P, Dreyling M. Copanlisib treatment in patients with relapsed or refractory indolent B-cell lymphoma: Subgroup analyses from the CHRONOS-1 study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx373.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Zinzani P, Wagner-Johnston N, Miller C, Ardeshna K, Tertreault S, Assouline S, Mayer J, Passamonti F, Lunin S, Pettitt A, Nagy Z, Tournilhac O, Abou-Nassar K, Crump M, Jacobsen E, De Vos S, Youssoufian H, Porter J, Prado S, Flinn I. DYNAMO: a PHASE 2 STUDY DEMONSTRATING THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE-REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_57] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- P. Zinzani
- Institute of Hematology Serágnoli; University of Bologna; Bologna Italy
| | | | - C. Miller
- Cancer Institute; St. Agnes Hospital; Baltimore USA
| | - K. Ardeshna
- Cancer Center; University College London; London UK
| | - S. Tertreault
- Department of Hematology; Florida Cancer Specialists Tallahassee; Tallahassee USA
| | - S. Assouline
- Division of Hematology; Jewish General Hospital; Montreal Canada
| | - J. Mayer
- Interni hematologicka; Onkologicka klinika-FN Brno; Brno Czech Republic
| | - F. Passamonti
- Oncology; Ospedale Di Circolo e Fondazione Macchi U.O. Ematologia; Varese Italy
| | - S. Lunin
- Hematology/Oncology; Florida Cancer Specialist Sarasotta; Sarasotta USA
| | - A. Pettitt
- Department of Molecular and Clinical Cancer Medicine, North West Cancer Research Centre; University of Liverpool; Liverpool UK
| | - Z. Nagy
- Belgyogyaszati Klinika; Semmelweis Egyetem, I. sz; Budapest Hungary
| | - O. Tournilhac
- Service d'hématologie; CHU Estaing; Clermont-Ferrand France
| | - K. Abou-Nassar
- Hematology; Centre intégré de santé et de services sociaux de l'Outaouais; Gatineau Canada
| | - M. Crump
- Hematology; Princess Margaret Cancer Center; Toronto Canada
| | - E. Jacobsen
- Hematology and Oncology; Beth Israel Deaconess Medical Center; Boston USA
| | - S. De Vos
- Hematology and Oncology; Ronald Reagan UCLA Medical Center; Los Angeles USA
| | | | - J. Porter
- Clinical Development; Verastem Inc.; Needham USA
| | - S. Prado
- Clinical Development; Verastem Inc.; Needham USA
| | - I. Flinn
- Hematology and Oncology; Sarah Cannon Research Institute; Nashville USA
| |
Collapse
|
37
|
Blakemore S, Daigle S, McDonald A, Morschhauser F, Ribrag V, Salles G, McKay P, Tilly H, Schmitt A, Le Gouill S, Fruchart C, Radford J, Zinzani P, Assouline S, Cartron G, Dickinson M, Morin R, Wu H, Sausen M, Clawson A, Ho P, Miao H. PRELIMINARY EVIDENCE OF A MOLECULAR PREDICTOR OF TAZEMETOSTAT RESPONSE, BEYOND EZH2 MUTATION, IN NHL PATIENTS VIA CHARACTERIZATION OF ARCHIVE TUMOR AND CIRCULATING TUMOR DNA. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_14] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
| | | | | | - F. Morschhauser
- Department of Hematology; Centre Hospitalier Universitaire; Lille France
| | - V. Ribrag
- Haematology; Gustave Roussy; Villejuif France
| | - G. Salles
- Hematology; Lyon-Sud Hospital Center; Pierre-Bénite France
| | - P. McKay
- Haematology; North Glasgow University Hospitals; Glasgow UK
| | - H. Tilly
- Hematology; Centre de lutte Contre le Cancer Henri Becquerel; Rouen France
| | - A. Schmitt
- Hematology; Institut Bergonié; Bordeaux France
| | - S. Le Gouill
- Service d'Hématologie Clinique; Universite De Nantes; Nantes France
| | - C. Fruchart
- Hematologie; Centre François Baclesse; Caen France
| | - J. Radford
- Molecular & Clinical Cancer Sciences (L5); The University of Manchester; Manchester UK
| | - P.L. Zinzani
- Hematology; University of Bologna; Bologna Italy
| | | | - G. Cartron
- Department of Hematology; CHU Montpellier; Montpellier France
| | - M. Dickinson
- Department of Haematology; Peter MacCallum Cancer Centre; Melbourne Australia
| | - R. Morin
- Molecular Biology and Biochemistry; Simon Fraser University; Burnaby BC Canada
| | - H. Wu
- Genomics and Oncology; Roche Molecular Systems; Pleasanton CA USA
| | - M. Sausen
- Research and Development; Personal Genome Diagnostics; Baltimore MD USA
| | - A. Clawson
- Biostatistics; Epizyme; Morrisville NC USA
| | - P.T. Ho
- Oncology Clinical Development; Epizyme; Cambridge MA USA
| | - H. Miao
- Oncology Clinical Development; Epizyme; Cambridge MA USA
| |
Collapse
|
38
|
Morschhauser F, Salles G, McKay P, Tilly H, Schmitt A, Gerecitano J, Johnson P, Le Gouill S, Dickinson M, Fruchart C, Lamy T, Chaidos A, Jurczak W, Opat S, Radford J, Zinzani P, Assouline S, Cartron G, Clawson A, Picazio N, Ribich S, Blakemore S, Larus J, Miao H, Ho P, Ribrag V. INTERIM REPORT FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMAS. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_3] [Citation(s) in RCA: 50] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- F. Morschhauser
- Department of Hematology; Centre Hospitalier Universitaire; Lille France
| | - G. Salles
- Hematology; Lyon-Sud Hospital Center; Pierre-Bénite France
| | - P. McKay
- Haematology; North Glasgow University Hospitals; Glasgow UK
| | - H. Tilly
- Hematology; Centre de lutte Contre le Cancer Henri Becquerel; Rouen France
| | - A. Schmitt
- Hematology; Institut Bergonié; Bordeaux France
| | - J. Gerecitano
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - P. Johnson
- Medical Oncology; Southampton General Hospital; Southampton UK
| | - S. Le Gouill
- Service d'Hématologie Clinique; Universite De Nantes; Nantes France
| | - M.J. Dickinson
- Department of Haematology; Peter MacCallum Cancer Centre; Melbourne Australia
| | - C. Fruchart
- Hematologie; Centre François Baclesse; Caen France
| | - T. Lamy
- Service d'Hématologie Clinique; CHU de Rennes; Rennes France
| | - A. Chaidos
- Haematology; Hammersmith Hospital; London UK
| | | | - S. Opat
- Clinical Haematology; Monash University; Clayton Australia
| | - J. Radford
- Molecular & Clinical Cancer Sciences (L5); The University of Manchester; Manchester UK
| | - P.L. Zinzani
- Hematology; University of Bologna; Bologna Italy
| | | | - G. Cartron
- Department of Hematology; CHU Montpellier; Montpellier France
| | | | - N. Picazio
- Clinical Operations; Epizyme; Cambridge USA
| | - S. Ribich
- Biological Sciences; Epizyme; Cambridge USA
| | | | - J. Larus
- Clinical Data Sciences; Epizyme; Cambridge USA
| | - H. Miao
- Oncology Clinical Development; Epizyme; Cambridge USA
| | - P.T. Ho
- Oncology Clinical Development; Epizyme; Cambridge USA
| | - V. Ribrag
- Haematology; Gustave Roussy; Villejuif France
| |
Collapse
|
39
|
Zinzani P, Thieblemont C, Melnichenko V, Osmanov D, Bouabdallah K, Walewski J, Majlis A, Fogliatto L, Caballero Barrigón M, Christian B, Gulbas Z, Özcan M, Salles G, Shipp M, Balakumaran A, Chlosta S, Chatterjee A, Armand P. Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE-170 phase 2 trial. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_49] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- P. Zinzani
- Institute of Hematology "L. e A. Seràgnoli"; University of Bologna; Bologna Italy
| | | | - V. Melnichenko
- Hematology; The National Medical Surgical Сentre named after N.I. Pirogov, Moscow; Russian Federation
| | - D. Osmanov
- Russian Academy of Medical Sciences; N.N. Blokhin Russian Oncological Research Center; Moscow Russian Federation
| | - K. Bouabdallah
- Hematology and Cell Therapy; Groupe Hospitalier du Haut Leveque; Pessac France
| | - J. Walewski
- Lymphoid Malignancy; Maria Sklodowska-Curie Institute - Oncology Center; Warsaw Poland
| | - A. Majlis
- Hematology, University of Chile; Hospital del Salvador; Santiago Chile
| | - L. Fogliatto
- Hematology; Hospital de Clinicas de Porto Alegre; Porto Alegre Brazil
| | | | - B. Christian
- Division of Hematology; Ohio State University - James Comprehensive Cancer Center; Columbus USA
| | - Z. Gulbas
- Hematologic Oncology; Anadolu Medical Center; Gebze Turkey
| | - M. Özcan
- Division of Hematology; Ankara University School of Medicine; Ankara Turkey
| | - G.A. Salles
- Hospices Civils de Lyon, Cancer Research Center of Lyon; Claude Bernard University Lyon; Pierre Benite France
| | - M.A. Shipp
- Division of Hematologic Neoplasia; Dana-Farber Cancer Institute; Boston USA
| | | | - S. Chlosta
- Clinical Research; Merck & Co., Inc.; Kenilworth USA
| | - A. Chatterjee
- Clinical Research; Merck & Co., Inc.; Kenilworth USA
| | - P. Armand
- Division of Hematologic Neoplasia; Dana-Farber Cancer Institute; Boston USA
| |
Collapse
|
40
|
Gerecitano J, Santoro A, Leppä S, Kim T, Kim W, Janssens A, Pedersen M, Reis D, Granvil C, Shen J, Zheng H, Childs B, Zinzani P. SAFETY RUN-IN OF COPANLISIB IN COMBINATION WITH RITUXIMAB PLUS BENDAMUSTINE IN PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN'S LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_187] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- J. Gerecitano
- Lymphoma Service/Developmental Therapy Clinic; Memorial Sloan-Kettering Cancer Center; New York USA
| | - A. Santoro
- Department of Oncology and Hematology; Humanitas Cancer Center, Humanitas Clinical and Research Center; Rozzano (MI) Italy
| | - S. Leppä
- Department of Oncology; Helsinki University Central Hospital Cancer Center; Helsinki Finland
| | - T. Kim
- Department of Internal Medicine; Seoul National University Hospital; Seoul Korea, Republic of
| | - W. Kim
- Division of Hematology and Oncology, Department of Medicine; Sungkyunkwan University School of Medicine, Samsung Medical Center; Seoul Korea, Republic of
| | - A. Janssens
- Dienst Haematologie, UZ Leuven; Leuven Belgium
| | - M. Pedersen
- Department of Hematology, HS Rigshospitalet; Copenhagen Denmark
| | - D. Reis
- Clinical Development, Bayer SA; São Paulo Brazil
| | - C. Granvil
- Clinical Pharmacology; Bayer HealthCare Pharmaceuticals Inc; Whippany NJ USA
| | - J. Shen
- Clinical Statistics; Bayer HealthCare Pharmaceuticals Inc; Whippany NJ USA
| | - H. Zheng
- Clinical Development; Bayer HealthCare Pharmaceuticals Inc; Whippany NJ USA
| | - B.H. Childs
- Clinical Development; Bayer HealthCare Pharmaceuticals Inc; Whippany NJ USA
| | - P. Zinzani
- Department of Hematology; Institute of Hematology "L. e A. Seràgnoli"- University of Bologna; Bologna Italy
| |
Collapse
|
41
|
Zinzani P, Fanale M, Chen R, Armand P, Johnson N, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos T, Tomita A, von Tresckow B, Shipp M, Zhang Y, Balakumaran A, Moskowitz C. PEMBROLIZUMAB MONOTHERAPY IN PATIENTS WITH PRIMARY REFRACTORY CLASSICAL HODGKIN LYMPHOMA: SUBGROUP ANALYSIS OF THE PHASE 2 KEYNOTE-087 STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_125] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- P.L. Zinzani
- Department of Experimental, Diagnostic and Specialty Medicine (DIMES); Institute of Hematology “L. e A. Seràgnoli,” University of Bologna; Bologna Italy
| | - M.A. Fanale
- Department of Lymphoma/Myeloma; The University of Texas MD Anderson Cancer Center; Houston USA
| | - R. Chen
- Department of Hematology & Hematopoietic Cell Transplantation; City of Hope National Medical Center; Duarte USA
| | - P. Armand
- Department of Hematologic Oncology; Dana-Farber Cancer Institute; Boston USA
| | - N. Johnson
- Division of Hematology; Jewish General Hospital; Montreal Canada
| | - P. Brice
- Department of Hematologic Oncology; Hôpital Saint-Louis; Paris France
| | - J. Radford
- Division of Molecular & Clinical Cancer Sciences; The University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre; Manchester UK
| | - V. Ribrag
- Department of Haematological Cancer; Institut Gustave Roussy; Villejuif France
| | - D. Molin
- Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology; Uppsala University; Uppsala Sweden
| | - T.P. Vassilakopoulos
- Department of Haematology & Bone Marrow Transplantation; National and Kapodistrian University of Athens, Laikon General Hospital; Athens Greece
| | - A. Tomita
- Department of Hematology & Oncology; Nagoya University Graduate School of Medicine *Current affiliation: Fujita Health University School of Medicine, Toyoake, Japan; Nagoya Japan
| | - B. von Tresckow
- Department of Internal Medicine; University Hospital Cologne; Cologne Germany
| | - M.A. Shipp
- Department of Hematologic Oncology; Dana-Farber Cancer Institute; Boston USA
| | - Y. Zhang
- Department of Biostatistics; LDS Oncology, Merck & Co., Inc.; Kenilworth USA
| | - A. Balakumaran
- Department of Oncology Clinical Development; Merck & Co., Inc.; Kenilworth USA
| | - C.H. Moskowitz
- Department of Hematologic Oncology; Memorial Sloan Kettering Cancer Center; New York USA
| |
Collapse
|
42
|
Prince H, Dummer R, Whittaker S, Horwitz S, Duvic M, Scarisbrick J, Quaglino P, Zinzani P, Wolter P, Sanches J, Ortiz-Romero P, Akilov O, Geskin L, Huen A, Wang Y, Palanca-Wessels M, Richhariya A, Feliciano J, Zhu Y, Lin H, Liu Y, Little M, Zagadailov E, Dalal M, Kim Y. PATIENT-REPORTED OUTCOMES AND QUALITY OF LIFE IN PATIENTS WITH CUTANEOUS T CELL LYMPHOMA: RESULTS FROM THE PHASE 3 ALCANZA STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_110] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- H.M. Prince
- Division of Cancer Medicine, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology; The University of Melbourne; Melbourne Australia
| | - R. Dummer
- Department of Dermatology; University Hospital Zürich; Zürich Switzerland
| | - S. Whittaker
- St John's Institute of Dermatology; Guys and St Thomas NHS Foundation Trust; London UK
| | - S. Horwitz
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - M. Duvic
- Department of Dermatology; The University of Texas MD Anderson Cancer Center; Houston USA
| | - J. Scarisbrick
- Department of Dermatology; University Hospital Birmingham; Birmingham UK
| | - P. Quaglino
- Department of Medical Sciences, Dermatologic Clinic; University of Turin; Turin Italy
| | - P.L. Zinzani
- Institute of Haematology; University of Bologna; Bologna Italy
| | - P. Wolter
- Department of General Medical Oncology; University Hospitals Leuven; Leuven Belgium
| | - J. Sanches
- Department of Dermatology; University of São Paulo Medical School; São Paulo Brazil
| | - P. Ortiz-Romero
- Department of Dermatology; University Hospital 12 de Octubre, Institute i+12 Medical School, University Complutense; Madrid Spain
| | - O. Akilov
- Department of Dermatology; University of Pittsburgh; Pittsburgh USA
| | - L. Geskin
- Department of Dermatology; University of Pittsburgh; Pittsburgh USA
| | - A. Huen
- Department of Dermatology; The University of Texas MD Anderson Cancer Center; Houston USA
| | - Y. Wang
- Biometrics; Seattle Genetics, Inc.; Bothell USA
| | | | - A. Richhariya
- Market Access & Health Economics; Seattle Genetics, Inc.; Bothell USA
| | - J. Feliciano
- Value and Access; Seattle Genetics, Inc.; Bothell USA
| | - Y. Zhu
- Global Statistics; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge USA
| | - H. Lin
- Biostatistics; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge USA
| | - Y. Liu
- Biostatistics; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge USA
| | - M. Little
- Oncology Clinical Research; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge USA
| | - E. Zagadailov
- Global Outcomes Research; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge USA
| | - M. Dalal
- Global Outcomes Research; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge USA
| | - Y.H. Kim
- Department of Dermatology; Stanford University School of Medicine and Stanford Cancer Institute; Stanford USA
| |
Collapse
|
43
|
Salles G, González Barca E, Jurczak W, Liberati A, Duell J, Nagy Z, Papajík T, Andre M, Kalakonda N, Dreyling M, Zinzani P, Ambarkhane S, Weirather J, Maddocks K. L-MIND: MOR208 COMBINED WITH LENALIDOMIDE (LEN) IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R-R DLBCL) - A SINGLE-ARM PHASE II STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_35] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- G. Salles
- Service d'Hématologie, Hospices Civils de Lyon; Centre Hospitalier Lyon Sud; Pierre Bénite France
| | - E. González Barca
- Department of Hematology, Institut Catalá d'Oncología; Hospital Duran i Reynals, IDIBELL; Barcelona Spain
| | - W. Jurczak
- Department of Hematology; Jagiellonian University; Kraków Poland
| | - A.M. Liberati
- SC Oncoematologia; Azienda Ospedaliera Santa Maria; Terni Italy
| | - J. Duell
- Medizinische Klinik und Poliklinik II; University Hospital of Würzburg; Würzburg Germany
| | - Z. Nagy
- First Department of Internal Medicine; Semmelweis University; Budapest Hungary
| | - T. Papajík
- Department of Hemato-Oncology; Palacký University Olomouc and the University Hospital Olomouc; Olomouc Czech Republic
| | - M. Andre
- Department of Hematology, Université catholique de Louvain; CHU UCL Namur; Yvoir Belgium
| | - N. Kalakonda
- Department of Haematology; Royal Liverpool University Hospital; Liverpool UK
| | - M. Dreyling
- Medizinische Klinik und Poliklinik III; University Hospital of LMU; Munich Germany
| | - P.L. Zinzani
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| | | | - J. Weirather
- Clinical Development; MorphoSys AG; Planegg Germany
| | - K. Maddocks
- Department of Internal Medicine, Division of Hematology; The Ohio State University Comprehensive Cancer Center; Columbus Ohio USA
| |
Collapse
|
44
|
Fanale M, Engert A, Younes A, Armand P, Ansell S, Zinzani P, Timmerman J, Collins G, Ramchandren R, Cohen J, De Boer J, Kuruvilla J, Savage K, Trneny M, Rodig S, Shipp M, Kato K, Sumbul A, Farsaci B, Santoro A. NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER AUTOLOGOUS TRANSPLANT: FULL RESULTS AFTER EXTENDED FOLLOW-UP OF THE PHASE 2 CHECKMATE 205 TRIAL. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_124] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- M. Fanale
- Department of Lymphoma/Myeloma; University of Texas MD Anderson Cancer Center; Houston USA
| | - A. Engert
- Department of Internal Medicine I; University Hospital of Cologne; Cologne Germany
| | - A. Younes
- Lymphoma Service; Memorial Sloan Kettering Cancer Center; New York USA
| | - P. Armand
- Medical Oncology; Dana-Farber Cancer Institute; Boston USA
| | - S. Ansell
- Division of Hematology; Mayo Clinic; Rochester USA
| | - P.L. Zinzani
- Institute of Hematology “L. e A. Seràgnoli; University of Bologna; Bologna Italy
| | - J.M. Timmerman
- Division of Hematology and Oncology; University of California, Los Angeles; Los Angeles USA
| | - G.P. Collins
- Oxford Cancer and Haematology Center; Churchill Hospital; Headington Oxford UK
| | - R. Ramchandren
- Department of Hematology/Oncology; Barbara Ann Karmanos Cancer Institute; Detroit USA
| | - J.B. Cohen
- Department of Hematology and Medical Oncology, Winship Cancer Institute; Emory University; Atlanta USA
| | - J.P. De Boer
- Department of Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital; Amsterdam Netherlands
| | - J. Kuruvilla
- Department of Medical Oncology and Hematology; University of Toronto and Princess Margaret Cancer Centre; Toronto Canada
| | - K.J. Savage
- Department of Medical Oncology; British Columbia Cancer Agency; Vancouver Canada
| | - M. Trneny
- Department of Hematology; Charles University in Prague and General University Hospital in Prague; Prague Czech Republic
| | - S. Rodig
- Department of Pathology; Brigham and Women's Hospital; Boston USA
| | - M. Shipp
- Center for Hematologic Oncology; Dana-Farber Cancer Institute; Boston USA
| | - K. Kato
- Global Clinical Research; Bristol-Myers Squibb; Lawrenceville USA
| | - A. Sumbul
- Global Biostatistics; Bristol-Myers Squibb; Lawrenceville USA
| | - B. Farsaci
- Oncology Biomarkers; Bristol-Myers Squibb; Lawrenceville USA
| | - A. Santoro
- Department of Medical Oncology and Hematology, Humanitas Cancer Center; Humanitas University; Rozzano Milan Italy
| |
Collapse
|
45
|
Kaplan J, Gordon L, Infante J, Popat R, Rambaldi A, Madan S, Patel M, Gritti G, El-Sharkawi D, Chau I, Radford J, Perez De Oteyza J, Zinzani P, Iyer S, Faucette S, Sheldon-Waniga E, Stumpo K, Shou Y, Carpio C, Bosch F. TAK-659, AN INVESTIGATIONAL REVERSIBLE DUAL SYK/FLT-3 INHIBITOR, IN PATIENTS WITH LYMPHOMA: UPDATED RESULTS FROM DOSE-ESCALATION AND EXPANSION COHORTS OF a PHASE 1 STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_60] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- J. Kaplan
- Department of Medicine; Northwestern University; Chicago USA
| | - L. Gordon
- Robert H Lurie Comprehensive Cancer Center; Northwestern University Feinberg School of Medicine; Chicago USA
| | - J. Infante
- Drug Development Unit; Sarah Cannon Research Institute/Tennessee Oncology; Nashville USA
| | - R. Popat
- NIHR Clinical Research Facility; UCLH; London UK
| | - A. Rambaldi
- Dipartimento di Oncologia ed Emato-Oncologia / Hematology and Bone Marrow Transplant Unit; Università degli Studi di Milano / Ospedale Papa Giovanni XXII; Bergamo Italy
| | - S. Madan
- Dipartimento di Oncologia ed Emato-Oncologia/Hematology and Bone Marrow Transplant Unit; Università degli Studi di Milano/Ospedale Papa Giovanni XXIII; Bergamo Italy
| | - M.R. Patel
- Hematology-Oncology; Florida Cancer Specialists/Sarah Cannon Research Institute; Sarasota USA
| | - G. Gritti
- Hematology and Bone Marrow Transplant Unit; Ospedale Papa Giovanni XXIII; Bergamo Italy
| | - D. El-Sharkawi
- Haematology; NIHR UCLH Clinical Research Facility; London UK
| | - I. Chau
- Department of Medicine; Royal Marsden Hospital; Surrey UK
| | - J. Radford
- Manchester Academic Health Science Centre; University of Manchester and the Christie NHS Foundation Trust; Manchester UK
| | | | - P. Zinzani
- Hematology, Institute of Hematology “Seragnoli”; University of Bologna; Bologna Italy
| | - S. Iyer
- Advanced Therapeutics, Institute of Academic Medicine; Houston Methodist Cancer Center; Houston USA
| | - S. Faucette
- Clinical Pharmacology; Takeda Pharmaceuticals International Co.; Cambridge USA
| | | | - K. Stumpo
- Oncology Clinical Research; Takeda Pharmaceuticals; Cambridge USA
| | - Y. Shou
- Oncology Clinical Research; Takeda Pharmaceuticals International Co.; Cambridge USA
| | - C. Carpio
- Hematology; University Hospital Vall d'Hebron; Barcelona Spain
| | - F. Bosch
- Hematology; University Hospital Vall d'Hebron; Barcelona Spain
| |
Collapse
|
46
|
Hohloch K, Scholz C, Windemuth-Kiesselbach C, Kolz J, Zinzani P, Cacchione R, Woijciech Jurczak W, Bischof-Delalaoye A, Truemper L. Radioimmunotherapy for follicular lymphoma achieves excellent lymphoma control in first line and relapse: 8-year follow-up data of 281 patients from the international RIT-registry. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_116] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- K. Hohloch
- Hematology and Oncology; Kantonspital Graubünden; Chur Switzerland
| | - C. Scholz
- Hematology and Oncology; Vivantes Klinikum Am Urban; Berlin Germany
| | | | - J. Kolz
- Hematology and Oncology; Georg August University Goettingen; Goettingen Germany
| | - P.L. Zinzani
- Istituto di Ematologia e Oncologia Medica; Università di Bologna; Bologna Italy
| | - R. Cacchione
- Hematology; CEMIC, Centro de Educación Médica e Investigaciones Clínical “Norberto Quirno”; Buenos Aires Argentina
| | | | - A. Bischof-Delalaoye
- Service de médecine nucléaire; Centre Hospitalier Universitaire Vaudois; Lausanne Switzerland
| | - L. Truemper
- Hematology and Oncology; Georg August University Goettingen; Goettingen Germany
| |
Collapse
|
47
|
Zinzani P, Ribrag V, Moskowitz C, Michot J, Kuruvilla J, Bartlett N, Balakumaran A, Chatterjee A, Chlosta S, Shipp M, Armand P. PHASE 1B STUDY OF PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (RRPMBCL): UPDATED RESULTS FROM THE KEYNOTE-013 TRIAL. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_50] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- P. Zinzani
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| | - V. Ribrag
- Medicine, Institut Gustave Roussy; Villejuif France
| | - C.H. Moskowitz
- Oncology; Memorial Sloan Kettering Cancer Center; New York USA
| | - J. Michot
- Medicine, Institut Gustave Roussy; Villejuif France
| | - J. Kuruvilla
- Oncology; Princess Margaret Cancer Centre and University of Toronto; Toronto Canada
| | - N. Bartlett
- Divisions of Hematology & Oncology; Washington University; St Louis USA
| | | | - A. Chatterjee
- Clinical Research, Merck & Co., Inc.; Kenilworth USA
| | - S. Chlosta
- Clinical Research, Merck & Co., Inc.; Kenilworth USA
| | - M.A. Shipp
- Division of Hematologic Neoplasia; Dana-Farber Cancer Institute; Boston USA
| | - P. Armand
- Lymphoma Clinical Research; Dana-Farber Cancer Institute; Boston USA
| |
Collapse
|
48
|
Michot J, Bouabdallah R, Doorduijn J, Vitolo U, Chiappella A, Kersten M, Zinzani P, Sarmiento R, Mosulen S, Petrarca M, Pourdehnad M, Hege K, Yang Z, Nikolova Z, Ribrag V. PHASE IB STUDY OF CC-122 IN COMBINATION WITH OBINUTUZUMAB (GA101): RELAPSED OR REFRACTORY (R/R) PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMAS (NHL). Hematol Oncol 2017. [DOI: 10.1002/hon.2437_37] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- J.M. Michot
- Hematology; Institut Gustave Roussy; Villejuif France
| | - R. Bouabdallah
- Department of Hematology; Institut Paoli-Calmettes; Marseilles France
| | - J.K. Doorduijn
- Hematology; Erasmus MC Cancer Institute; Rotterdam Netherlands
| | - U. Vitolo
- Dipartimento di Oncologia ed Ematologia; Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino; Torino Italy
| | - A. Chiappella
- Dipartimento di Oncologia ed Ematologia; Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino; Torino Italy
| | - M.J. Kersten
- Hematology; Academic Medical Center; Amsterdam Netherlands
| | - P.L. Zinzani
- Institute of Hematology "Seràgnoli"; University of Bologna; Bologna Italy
| | - R. Sarmiento
- Translational Development; Celgene Institute for Translational Research Europe; Seville Spain
| | - S. Mosulen
- Translational Development; Celgene Institute for Translational Research Europe; Seville Spain
| | - M. Petrarca
- Translational Medicine; Celgene Corporation; San Francisco California USA
| | - M. Pourdehnad
- Translational Medicine; Celgene Corporation; San Francisco California USA
| | - K. Hege
- Translational Medicine; Celgene Corporation; San Francisco California USA
| | - Z. Yang
- BioStats, Celgene Corporation; Berkeley Heights; New Jersey USA
| | - Z. Nikolova
- Executive Research; Celgene Institute for Translational Research Europe; Seville Spain
| | - V. Ribrag
- Hematology; Institut Gustave Roussy; Villejuif France
| |
Collapse
|
49
|
Pellegrini C, Pulsoni A, Rigacci L, Patti C, Gini G, Tani M, Rusconi C, Romano A, Vanazzi A, Hohaus S, Mazza P, Molica S, Corradini P, Gaudio F, Ronconi F, Pinto A, Pavone V, Volpetti S, Visentin A, Bonfichi M, Schiavotto C, Spina M, Carella A, Argnani L, Zinzani P. REAL LIFE EXPERIENCE WITH BRENTUXIMAB VEDOTIN: THE ITALIAN STUDY ON 234 RELAPSED/REFRACTORY HODGKIN'S LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_29] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- C. Pellegrini
- Institute of Hematology "L. e A. Seràgnoli"; University of Bologna; Bologna Italy
| | - A. Pulsoni
- Hematology, Department of Cellular Biotechnologies and Hematology; Sapienza University; Rome Italy
| | - L. Rigacci
- Hematology Department; University and Hospital Careggi; Florence Italy
| | - C. Patti
- Hematology; Azienda Ospedali Riuniti Villa Sofia Cervello; Palermo Italy
| | - G. Gini
- Hematology; Ospedali Riuniti; Ancona Italy
| | - M. Tani
- Hematology; Santa Maria delle Croci Hospital; Ravenna Italy
| | - C. Rusconi
- Division of Hematology Niguarda Cancer Center; Niguarda Hospital; Milan Italy
| | - A. Romano
- Hematology, Azienda Policlinico-OVE; University of Catania; Catania Italy
| | - A. Vanazzi
- Division of Clinical Haemato-Oncology; IEO; Milan Italy
| | - S. Hohaus
- Institute of Hematology; Catholic Unicversityof the Sacred Heart; Rome Italy
| | - P. Mazza
- Department of Hematology-Oncology; Ospedale Moscati; Taranto Italy
| | - S. Molica
- Hematology; Azienda Ospedaliera Pugliese-Ciaccio; Catanzaro Italy
| | - P. Corradini
- Hematology; Fondazione IRCCS Istituto Nazionale dei Tumori; Milan Italy
| | - F. Gaudio
- Hematology; Policlinico di Bari; Bari Italy
| | - F. Ronconi
- Division of Hematology and Stem Cell Transplantation Unit; Cardarelli Hospital; Naples Italy
| | - A. Pinto
- Hematology-Oncology and Stem Cell Transplantation Unit; National Cancer Institute, Fondazione Pascale, IRCCS; Naples Italy
| | - V. Pavone
- Hematology; Ospedale G. Panico; Lecce Italy
| | - S. Volpetti
- Hematology; Azienda Sanitaria Universitaria Integrata; Udine Italy
| | - A. Visentin
- Hematology and Clinical Immunology Unit, Department of Medicine; University of Padua; Padova Italy
| | - M. Bonfichi
- Hematology; IRCCS Policlinico San Matteo; Pavia Italy
| | | | - M. Spina
- Division of Medical Oncology A; National Cancer Institute; Aviano Italy
| | - A. Carella
- Division of Hematology 1; IRCCS A.O.U. San Martino IST; Genoa Italy
| | - L. Argnani
- Institute of Hematology "L. e A. Seràgnoli"; University of Bologna; Bologna Italy
| | - P. Zinzani
- Institute of Hematology "L. e A. Seràgnoli"; University of Bologna; Bologna Italy
| |
Collapse
|
50
|
Broccoli A, Nanni C, Cappelli A, Bacci F, Gasbarrini A, Zanoni L, Brocchi S, Spagnolo S, Piovani C, Argnani L, Boriani S, Sabattini E, Golfieri R, Fanti S, Zinzani P. PET/CT-GUIDED BIOPSY FOR THE DIAGNOSIS OF LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2440_9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- A. Broccoli
- Hematology, Institute of Hematology “Lorenzo e Ariosto Seràgnoli”; University of Bologna; Bologna Italy
| | - C. Nanni
- Nuclear Medicine, Medicina Nucleare Metropolitana, Sant'Orsola-Malpighi Hospital; University of Bologna; Bologna Italy
| | - A. Cappelli
- Radiology, Radiology Unit; Sant'Orsola-Malpighi Hospital; Bologna Italy
| | - F. Bacci
- Hemopathology, Hemopathology Unit; Sant'Orsola-Malpighi Hospital; Bologna Italy
| | - A. Gasbarrini
- Oncological and Degenerative Spine Surgery; Institute of Orthopedics “Rizzoli”; Bologna Italy
| | - L. Zanoni
- Nuclear Medicine, Medicina Nucleare Metropolitana, Sant'Orsola-Malpighi Hospital; University of Bologna; Bologna Italy
| | - S. Brocchi
- Radiology, Radiology Unit; Sant'Orsola-Malpighi Hospital; Bologna Italy
| | - S. Spagnolo
- Hemopathology, Hemopathology Unit; Sant'Orsola-Malpighi Hospital; Bologna Italy
| | - C. Piovani
- Oncological and Degenerative Spine Surgery; Institute of Orthopedics “Rizzoli”; Bologna Italy
| | - L. Argnani
- Hematology, Institute of Hematology “Lorenzo e Ariosto Seràgnoli”; University of Bologna; Bologna Italy
| | - S. Boriani
- Oncological and Degenerative Spine Surgery; Institute of Orthopedics “Rizzoli”; Bologna Italy
| | - E. Sabattini
- Hemopathology, Hemopathology Unit; Sant'Orsola-Malpighi Hospital; Bologna Italy
| | - R. Golfieri
- Radiology, Radiology Unit; Sant'Orsola-Malpighi Hospital; Bologna Italy
| | - S. Fanti
- Nuclear Medicine, Medicina Nucleare Metropolitana, Sant'Orsola-Malpighi Hospital; University of Bologna; Bologna Italy
| | - P.L. Zinzani
- Hematology, Institute of Hematology “Lorenzo e Ariosto Seràgnoli”; University of Bologna; Bologna Italy
| |
Collapse
|